Clinical Trials Browser

Prostatic Neoplasms

Fallopian Tube Neoplasms, Ovarian Neoplasms

Head and Neck Neoplasms

Pancreatic Neoplasms

Prostate Adenocarcinoma

Carcinoma, Ovarian Epithelial

Unilateral Breast Neoplasms

Pancreatic Adenocarcinoma

Uterine Neoplasms, Endometrial Neoplasms

Pancreatic Neoplasms

Pancreatic Neoplasms

Fallopian Tube Neoplasms, Ovarian Neoplasms

Mesothelioma, Malignant, Mesothelioma, Recurrence

Prostate Carcinoma Metastatic to the Bone

Urothelial Cancer

Ovarian Neoplasms

Ovarian Neoplasms

Breast Neoplasms, Ovarian Neoplasms

Breast Neoplasms

Neoplasms, Ovarian Neoplasms

Uveal Melanoma, Carcinoma, Renal Cell, Mesothelioma, Cholangiocarcinoma

Ovarian Neoplasms

Platinum-resistant Recurrent Clear Cell Ovarian Cancer

Ovarian Neoplasms

Carcinoma, Transitional Cell

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms

Ovarian Neoplasms

Sarcoma, Ewing

Clinical Trials

Testing the Addition of a New Anti-Cancer Drug, Niraparib, to the Usual Treatment (Hormone and Radiation Therapy) for Prostate Cancer With a High Chance of Recurring

MONITOR-UK

Study Evaluating the Efficacy of Niraparib and Dostarlimab (TSR-042) in Recurrent/Metastatic HNSCC

Niraparib in Patients With Pancreatic Cancer

A Trial of Niraparib in Platinum-Sensitive Castration-Resistant Prostate Cancer With DNA Repair Defects

REFIRM

Abemaciclib and Niraparib Before Surgery for the Treatment of Hormone Receptor Positive HER2 Negative Breast Cancer

Parpvax

Trial of Maintenance With Niraparib- Uterine Serous Carcinoma

Niraparib + Dostarlimab + RT in Pancreatic Cancer

Niraparib and Dostarlimab for the Treatment of Germline or Somatic BRCA1/2 and PALB2 Mutated Metastatic Pancreatic Cancer

EUDARIO

NERO

Phase IB Trial of Radium-223 and Niraparib in Patients With Castrate Resistant Prostate Cancer (NiraRad)

NICARAGUA

NiQoLe

ANITA

Evaluation of the Safety and Tolerability of Niraparib With Everolimus in Advanced Gynecologic Malignancies and Breast

LUZERN

NEOPRIMA

A Trial of Niraparib in BAP1 and Other DNA Damage Response (DDR) Deficient Neoplasms (UF-STO-ETI-001)

Arterial Hypertension Related to PARP Inhibitors (ArteRIB)

Effectiveness and Safety of Niraparib as First-line Maintenance Therapy for Ovarian Cancer: a Real-world Study

CC-ANNIE

AVANOVA

Maintenance With Niraparib In Patients With Advanced Urothelial Cancer After 1st-line Platinum-based Chemotherapy

Pancytopenia Related to PARP Inhibitors (PancytoRIB)

Niraparib as Maintenance Therapy in Patients With Platinum Sensitive Recurrent Ovarian Cancer

Real-life Use of Niraparib in a Patient Access Program in Norway

ESP1/SARC025 Global Collaboration: A Phase I Study of a Combination of the PARP Inhibitor, Niraparib and Temozolomide and/or Irinotecan Patients With Previously Treated, Incurable Ewing Sarcoma